MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- AJANTA PHARMA LTD. (pharmaceuticals)
- Latest 8 Quarter Result
AJANTA PHARMA Quarterly Results 
(AJPH)
Here are the latest quarterly results of AJANTA PHARMA. For more details, see the AJANTA PHARMA financial fact sheet and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
AJANTA PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-17* |
3
Jun-17* |
3
Sep-17* |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 4,768 | 4,731 | 5,404 | 5,871 | 5,303 | 5,110 | 5,441 | 4,851 | |
| Other income | Rs m | 24 | 48 | 92 | 152 | 52 | 81 | 152 | 44 | |
| Turnover | Rs m | 4,792 | 4,779 | 5,496 | 6,022 | 5,356 | 5,191 | 5,594 | 4,895 | |
| Expenses | Rs m | 3,154 | 3,457 | 3,567 | 3,896 | 3,908 | 3,535 | 3,779 | 3,778 | |
| Gross profit | Rs m | 1,614 | 1,275 | 1,837 | 1,975 | 1,395 | 1,575 | 1,662 | 1,073 | |
| Depreciation | Rs m | 189 | 134 | 146 | 150 | 166 | 172 | 175 | 187 | |
| Interest | Rs m | 9 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | |
| Profit before tax | Rs m | 1,440 | 1,187 | 1,783 | 1,975 | 1,280 | 1,483 | 1,638 | 930 | |
| Tax | Rs m | 300 | 239 | 464 | 501 | 335 | 425 | 385 | 261 | |
| Profit after tax | Rs m | 1,140 | 948 | 1,319 | 1,475 | 945 | 1,058 | 1,254 | 669 | |
| Gross profit margin | % | 33.8 | 26.9 | 34.0 | 33.6 | 26.3 | 30.8 | 30.5 | 22.1 | |
| Effective tax rate | % | 20.8 | 20.2 | 26.0 | 25.3 | 26.2 | 28.7 | 23.5 | 28.0 | |
| Net profit margin | % | 23.9 | 20.0 | 24.4 | 25.1 | 17.8 | 20.7 | 23.0 | 13.8 | |
| Diluted EPS | Rs | 13.0 | 10.8 | 15.0 | 16.8 | 10.7 | 12.0 | 14.3 | 7.6 | |
| Diluted EPS (TTM) | Rs | 57.6 | 54.8 | 55.0 | 55.5 | 53.3 | 54.5 | 53.8 | 44.6 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: AJANTA PHARMA 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: PFIZER NATCO PHARMA FULFORD INDIA STRIDES PHARMA SCIENCE MERCK
Compare AJANTA PHARMA With: PFIZER NATCO PHARMA FULFORD INDIA STRIDES PHARMA SCIENCE MERCK
Compare AJANTA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Tanks 495 Points, Jet Airways in Focus and Other Top Stocks in Action Today(Pre-Open)
On Monday, share markets in India opened on a negative note and ended the day deep in red after a volatile day of trading.
Views on news
AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)
Feb 1, 2019 | Updated on Feb 1, 2019For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)
Nov 6, 2018 | Updated on Nov 6, 2018For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
3 Indian Stocks with Amazon-Like Potential(Profit Hunter)
Apr 10, 2019We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.
This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)
Apr 10, 2019How Dell got its mojo back.
This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)
Apr 12, 2019This critical business strategy has enabled companies to scale their operations faster.
Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)
Apr 12, 2019Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.
A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)
Apr 11, 2019A must have checklist for every investor in the Indian stock market.
More|
| |
AJANTA PHARMA SHARE PRICE
Apr 22, 2019 (Close)
TRACK AJANTA PHARMA
- Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AJANTA PHARMA
AJANTA PHARMA 5-YR ANALYSIS
COMPARE AJANTA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.